Gautam Patel - Mar 3, 2025 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Director
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Stock symbol
AMRX
Transactions as of
Mar 3, 2025
Transactions value $
-$712,000
Form type
4
Date filed
3/5/2025, 07:12 PM
Previous filing
Feb 5, 2025
Next filing
Apr 2, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Sale -$712K -80K -4.24% $8.90 1.81M Mar 3, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15,2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.73 to $8.98 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.